Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema

NCT02924987 is registered in ClinicalTrials.gov with Maisonneuve-Rosemont Hospital as lead sponsor.

NCT NCT02924987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02924987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema
Lead sponsor
Maisonneuve-Rosemont Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
November 30, 2016
Completion date
November 30, 2017
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema